Amgen's immunology drug results —The Novo Nordisk Senate hearing —Sanofi's soul-searching Read on to learn more.

After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma fold, taking up the top science spot at Sanofi.

Sanofi named a new chief scientific officer this week, part of a series of moves aimed at redefining the company.

Sanofi has appointed Mike Quigley, a former executive at Gilead and Bristol Myers Squibb, as the French pharma's next chief ...

Mike Tyson and Jake Paul's upcoming fight has been dismissed as "not real" by iconic boxing commentator Jim Lampley, who joins many critics in questioning the legitimacy of the bout. Originally ...

Sanofi Consumer Healthcare India Limited has been listed on the BSE and National Stock Exchange (NSE). SCHIL’s demerger from Sanofi India Limited, executed under the Scheme of Arrangement, was ...

In 2020, Sanofi invested nearly 500 million euros ($554 million) to build what it then called its Evolutive Vaccine Facility (EVF). The idea later evolved into including the manufacture of biologics.

Sanofi has made a late entry to the radioligand party, paying 100 million euros ($110 million) upfront for global rights to a neuroendocrine tumor treatment that is nearing a filing for approval.

As part of its effort to develop innovative treatments for people living with rare cancers, Sanofi has entered into an exclusive licensing agreement with RadioMedix, Inc., a US clinical-stage ...

Sanofi agreed to pay up to 320 million euros ($352.4 million) to U.S. company RadioMedix and the biotechnology subsidiary of nuclear-fuel supplier Orano to license a potential treatment for rare ...

PARIS & HOUSTON, September 12, 2024--(BUSINESS WIRE)--Regulatory News: As part of its effort to develop innovative treatments for people living with rare cancers, Sanofi has entered into an ...

Sanofi is following several of its big pharma industry peers into radiopharmaceuticals, striking a deal for a clinical-stage therapy now in discussion for a regulatory submission as a treatment ...